Lipocine Presents Promising LPCN 2401 Data at ObesityWeek

An announcement from Lipocine ( (LPCN) ) is now available.

On November 4, 2025, Lipocine Inc. presented clinical data for LPCN 2401 at the ObesityWeek® conference in Atlanta, highlighting its potential in improving body composition and liver health in men with obesity. The Phase 2 trial results demonstrated that LPCN 2401, both alone and combined with vitamin E, significantly increased lean mass, reduced fat mass, and improved liver health markers compared to placebo, with no concerning safety signals observed over 72 weeks of exposure.

The most recent analyst rating on (LPCN) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Lipocine stock, see the LPCN Stock Forecast page.

Spark’s Take on LPCN Stock

According to Spark, TipRanks’ AI Analyst, LPCN is a Neutral.

Lipocine’s overall stock score is primarily impacted by its financial performance and valuation. While the company shows signs of financial recovery with a strong balance sheet, ongoing profitability challenges and negative cash flow generation weigh heavily on the score. The technical analysis indicates a bearish trend, further contributing to the lower score. The lack of earnings call data and corporate events means these factors do not influence the score.

To see Spark’s full report on LPCN stock, click here.

More about Lipocine

Lipocine Inc. is a biopharmaceutical company that utilizes its proprietary technology platform to develop innovative products with effective oral delivery. The company focuses on creating differentiated, patient-friendly oral delivery options targeting large markets with significant unmet medical needs, including treatments for postpartum depression, epilepsy, essential tremor, obesity management, and liver cirrhosis.

Average Trading Volume: 31,864

Technical Sentiment Signal: Sell

Current Market Cap: $14.36M

Learn more about LPCN stock on TipRanks’ Stock Analysis page.